Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)

Inclusion Criteria: Written informed consent * Age of ≥ 60 years at study inclusion with a limited number of "unsuited" patients younger than 60 years * Histologically proven advanced and/or metastatic STS, intermediate/high grade * Presence of measurable disease according to RECIST 1.1. (optional, according to local clinical practice) * Patients indicated for 1st line treatment with trabectedin according to local SmPC * ECOG Performance Status 0, 1 or 2 * bone marrow function according to local SmPC * hepatic function according to local SmPC * Ability to understand and follow study-related instructions Exclusion Criteria: * Histologically proven advanced and/or metastatic STS of the following tumor types: * Embryonal rhabdomyosarcoma * Chondrosarcoma (excluding extraskeletal myxoid chondrosarcoma) * Osteosarcoma (excluding extraskeletal osteosarcoma) * Ewing tumors/primitive neuroectodermal tumor * Gastrointestinal stromal tumors * Dermatofibrosarcoma protuberans * Use of any investigational agent within 28 days prior to treatment start * Exclusion periods from other studies or simultaneous participation in other clinical studies * Contraindications according to the local SmPC of Yondelis® (see Appendix A) * Subject is in custody by order of an authority or a court of law * Previous assignment to the E-Trab study (An individual subject may only be included once in the study) * Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety